Morgan Stanley analyst Emmet Kelly resumed coverage of Cellnex with an Equal Weight rating and EUR 44 price target. The company’s organic growth story is underappreciated, but its step back from expansionary acquisitions removes an opportunity to "turbo-charge" its bottom line, Kelly tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly